Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

947
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
947
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.5K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.5K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.8K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

925
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
925
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

328
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
328

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same author

TQC3721: Expanding the Role of Dual Phosphodiesterase 3/4 Inhibition in COPD Management.

Chest·2026
Same author

Mucus plugs in COPD and cardiovascular mortality: An emerging risk pathway and the therapeutic potential of mucolytic strategies.

Respiratory medicine·2026
Same author

IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.

Lung·2026
Same author

Respiratory health in a changing environment: environment-adaptive therapies and revised dosing strategies.

Expert review of respiratory medicine·2026
Same author

Redox signaling in chronic airway diseases: pathogenic mechanisms and therapeutic implications.

Frontiers in physiology·2026

Related Experiment Video

Updated: Mar 13, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.5K

Fixed-Dose Combination Inhalers.

Mario Cazzola1, Maria Gabriella Matera2

  • 1Department of Systems Medicine, Respiratory Pharmacology Research Unit, University of Rome Tor Vergata, Rome, Italy. mario.cazzola@uniroma2.it.

Handbook of Experimental Pharmacology
|October 27, 2016
PubMed
Summary
This summary is machine-generated.

Fixed-dose combination therapies, including inhaled corticosteroids/long-acting beta-agonists (ICS/LABA) and long-acting antimuscarinic agents/long-acting beta-agonists (LAMA/LABA), simplify treatment for asthma and COPD. Triple therapy (ICS/LABA/LAMA) offers potential benefits for severe disease.

Keywords:
Antimuscarinic agentsFixed-dose combinationsInhaled corticosteroidsβ2-agonists

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.1K

Related Experiment Videos

Last Updated: Mar 13, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.5K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.1K

Area of Science:

  • Respiratory Medicine
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Simplifying management and improving adherence are key goals in asthma and COPD treatment.
  • Fixed-dose combination (FDC) therapies reduce medication burden and may enhance therapeutic effects.
  • Current FDCs include inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) and long-acting beta-agonist/long-acting antimuscarinic agent (LABA/LAMA).

Purpose of the Study:

  • To review the role and benefits of various fixed-dose combination therapies in managing asthma and COPD.
  • To explore the potential of triple therapy (ICS/LABA/LAMA) in complex respiratory conditions.

Main Methods:

  • Review of available literature and clinical development of ICS/LABA, LABA/LAMA, and triple FDCs.
  • Analysis of the pharmacological rationale and clinical utility of combining different bronchodilator and anti-inflammatory agents.

Main Results:

  • ICS/LABA FDCs are established treatments for asthma and severe COPD.
  • LABA/LAMA FDCs offer optimized bronchodilation and are available in once-daily and twice-daily formulations.
  • Triple ICS/LABA/LAMA FDCs are logical for severe disease, potentially allowing lower individual agent doses and improved side effect profiles.

Conclusions:

  • Fixed-dose combination therapies significantly simplify treatment regimens for asthma and COPD.
  • Triple therapy (ICS/LABA/LAMA) represents a promising approach for patients with severe, poorly controlled disease.
  • The development of novel FDCs aims to improve patient adherence and therapeutic outcomes in chronic respiratory diseases.